

# Antibody Engineering & Therapeutics

December 11-15, 2017  
Manchester Grand Hyatt  
San Diego, CA

Annual Meeting  
of the  
**ANTI  
BODY  
SOCI  
ETY**

**THE LARGEST MEETING BRINGING YOU THE LATEST  
ANTIBODY SCIENCE, TECHNOLOGIES AND PARTNERS  
NEEDED TO ACCELERATE NEXT GENERATION  
ANTIBODIES TOWARDS COMMERCIAL SUCCESS**

**The Most Innovative Science** Presented by Leading Industry and Academic Experts

**The Largest Exhibition** Devoted to Antibody Engineering

**The Leading Forum** to Partner with Global Antibody Innovators and Suppliers

**Keynotes Speakers Share Strategies  
to Accelerate Your Antibody Molecules**

## **DECIPHERING THE HUMAN IMMUNOME**

**James E. Crowe, Jr., M.D.,**  
Director, Vanderbilt Vaccine Center,  
Vanderbilt University Medical Center



## **PARACRINE DELIVERY**

**Andreas Plückthun, Ph.D.,**  
Professor and Director,  
Department of Biochemistry,  
University of Zürich, Switzerland




## **BIOLOGIC DRUG DELIVERY ACROSS THE BLOOD-BRAIN BARRIER WITH IgG FUSION PROTEINS**

**William M. Pardridge, M.D.,**  
Distinguished Professor Emeritus, UCLA and  
Founder and Chief Scientific Officer, ArmaGen



## **OCRELIZUMAB IN RELAPSING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS**

**Peter Chin, M.D.**  
Group Medical Director, Neuroscience,  
SPECTRUM Medical Unit, US Medical Affairs,  
Genentech



**Register by June 30 and Save Up to \$600** [www.antibodyeng.com](http://www.antibodyeng.com)

# PRELIMINARY AGENDA (as of June 23, 2017, subject to change)

## PRE-CONFERENCE TRAINING COURSE

Monday, December 11, 2017, 9:00am-5:00pm

### Introduction to Antibody Engineering

*Instructor:* David Bramhill, Ph.D., Bramhill Consulting, LLC and Research, Corporation Technologies

\*Additional registration fee applies. See the pricing tier on page 8 or visit the website for more details

## PRE-CONFERENCE WORKSHOPS

Monday, December 11, 2017, 1:00pm-5:00pm

### Workshop A: Selecting Antibodies against Cell-Surface Targets

*Workshop Moderator:* Andrew Bradbury, M.D., Ph.D., Research Scientist and Group Leader, Los Alamos National Laboratories

### Workshop B: Developability of Antibodies

*Workshop Moderator:* Mark Chiu, Associate Director of Development, Janssen R&D

\*Additional registration fee applies. See the pricing tier on page 8 or visit the website for more details

## MAIN CONFERENCE

Tuesday-Friday, December 12-15, 2017

### ENGINEERING AND APPLICATION OF THERAPEUTIC ANTIBODIES FOR NEURODEGENERATIVE DISEASES

*Session Co-Chairs:*

Cynthia A. Lemere, Ph.D., Associate Professor of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School

Anne Messer, Ph.D., Professor of Biomedical Sciences, University at Albany and Principal Investigator, Neural Stem Cell Institute, Regenerative Research Foundation

James S. Huston, Ph.D., Chairman, The Antibody Society; Managing Member, Huston BioConsulting, LLC

### Towards Development of Antibody Therapy for C9orf72 ALS/FTD

Laura P.W. Ranum, Ph.D., Director, Center for NeuroGenetics, Kitzman Family Professor of Molecular Genetics and Microbiology, College of Medicine, University of Florida

### Antibody Therapy for Alzheimer's Disease – Key Challenges

Christoph Hock, M.D., Professor and Director, Institute for Regenerative Medicine (IREM), University of Zurich and Co-Founder, Neurimmune, Switzerland

### Altering APP Processing with a Proteolytic Diabody

Michael Sierks, Ph.D., Professor, Chemical Engineering, Arizona State University

### Tau Immunotherapy

Peter Davies, Feinstein Institute for Medical Research, North Shore/LIJ Health System

### PD Immunotherapy – A-Syn

Eliezer Masliah, M.D., Director, Division of Neurosciences, National Institutes of Aging, NIH

## BIOLOGICAL IMPACT OF FC RECEPTOR ENGAGEMENT

*Session Co-Chairs:*

Trudi Veldman Ph.D., Senior Director Biologics, AbbVie Bioresearch Center  
Chung-Ming Hsieh, Executive Director, Biologics Discovery Boston, Merck Research Laboratories

### SKY59: Novel Recycling Antibody against C5 with Improved Pharmacokinetics for the Treatment of Complement-mediated Diseases

Kenta Haraya, Ph.D., Scientist, Research Division, Biologics Discovery, Chugai Pharmaceutical Co Ltd., Japan

### Novel Effector Function Attenuating Mutations That Maintain Antibody Stability and Reduce Toxicity

James A. Ernst, Ph.D., Senior Scientist & Group Leader, Department of Protein Sciences, Genentech

### Selective FcγR Engagement by Agonistic Anti-CD40 Abs

Rony Dahan, Ph.D., Principal Investigator, Department of Immunology, Weizmann Institute of Science, Israel

### Antibody Optimization for Treg Depletion in Cancer Therapy

Frederick Arce Vargas, M.D. Ph.D., Research Associate, University College London Cancer Institute, United Kingdom

### Potent Antitumor Activity of IL2-Fc Requires Fc-mediated Depletion of Tregs

Daniel Christ, Ph.D., Associate Professor and Head Antibody Therapeutics, Director Centre for Targeted Therapy, Immunology Program, Garvan Institute of Medical Research

## IMMUNO-ONCOLOGY: CHECKPOINTS

*Session Chair:*

James Larrick, M.D., Ph.D., Managing Director and Chief Medical Officer, Panorama Research Institute and Velocity Pharmaceutical Development

### SIMPLE Antibody™ Platform Generates Unique Species Cross-reactive Antibodies against Immune Checkpoints

Erik Hofman, Ph.D., Senior Scientist, Research Department, Argenx, Belgium

### A Novel Cytokine Receptor Agonistic Antibody by Design

Cheng-I Wang, Ph.D., Senior Principal Investigator, Singapore Immunology Network, Biomedical Sciences Institutes, ASTAR, Singapore

### Cow Ultralong CDR3 Antibodies Targeting Exhausted T-cells

Vaughn Smider M.D., Ph.D., Associate Professor, Molecular Medicine, The Scripps Research Institute

### Immuno-oncology and Prostate Cancer

Xin Lu, Professor M.D., University of Notre Dame

### Boosting Cancer Immunotherapy with Combined Immunomodulatory Drugs

Mickey Hu, Ph.D., Scientist, Panorama Institute of Molecular Medicine

## ROLE OF POST-TRANSLATIONAL MODIFICATION IN ANTIBODY FUNCTION

### Session Co-Chairs:

Dennis R. Burton, Ph.D., Professor, Department of Immunology and Microbial Science, The Scripps Research Institute

Paul Parren, Ph.D., Senior Vice President and Scientific Director, Genmab, *The Netherlands*

### Integrative Mass Spectrometric Structural Analysis of Glycoprotein Therapeutics and Its Usage to Evaluate and Score Biosimilarity

Albert J. R. Heck, Ph.D., Professor and Science Faculty, Utrecht University, *The Netherlands*

### Post-translational Modification of Antibodies in Rheumatoid Arthritis

Leendert A. Trouw Ph.D., Assistant, Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden, *The Netherlands*

### Regulation of Autoantibody Activity by the IL-23–TH17 Axis and Its Impact on Autoimmune Disease

Gerhard Krönke, M.D., Professor of Translational Immunology, Department of Internal Medicine 3, Institute of Rheumatology and Immunology, University of Erlangen-Nuremberg Germany

### Fc Fucosylation and Sialylation and Antibody Effector Function

Jeffrey Ravetch, Ph.D., Professor, Rockefeller University

### Sulfation of Broadly Neutralizing HIV Antibodies

Raiees Andrabi, Research Associate, The Burton Lab, The Scripps Research Institute

## ANTIBODY BASED INNOVATIONS IN THE TUMOR MICROENVIRONMENT

### Session Co-Chairs:

Kerry A. Chester, Ph.D., Professor of Molecular Medicine, UCL Cancer Institute, University College London, *United Kingdom*

Janine Schuurman, Ph.D., Vice President, Research, Genmab, *The Netherlands*

### Protia – Bispecific T-Cell Engagers Designed for Local Activation in the Tumor Environment

Volker Schellenberger, Ph.D., CEO and President, Amunix

### Immuno-Viral Therapy for Solid Tumors

Maria Navarro, M.D., Project & Operations Manager, Icell Kealex Therapeutics

### Costimulation of Immune Cells in the Tumor Microenvironment via Bispecific DART® and TRIDENT™ Molecules

Syd Johnson, Ph.D., Vice President, Antibody Engineering, MacroGenics

### Harnessing Fc Gamma Receptor Biology to Optimize Antibodies Targeting TNFR Superfamily Members

Nick Wilson, Ph.D., Executive Director of Immuno-modulatory Drug Discovery, Agenus

### mRNA Vaccination and Combination Therapy with Immunomodulating Antibodies

Sebastian Kreiter, Head, Tron/BioNTech, *Germany*

### An Update on the Darzalex Story

Kate Sasser, Ph.D., Vice President, Head of Oncology Translational Research, Janssen

## OVERCOMING DELIVERY CHALLENGES INCLUDING BRAIN AND INTRACELLULAR TARGETS

### Session Co-Chairs:

Paul J. Carter, Ph.D., Senior Director and Staff Scientist, Antibody Engineering, Genentech, Inc.

Andreas Plückthun, Ph.D., Professor and Director, Department of Biochemistry, University of Zürich, *Switzerland*

### Bacterial Secretion Systems

Thomas Marlovits, Professor, Institute of Molecular Pathology, *Austria*

### Nanobodies as Inhaled Biotherapeutics for Lung Diseases, with ALX-0171 (anti-RSV) as a Case Study

Antonin De Fourgerolles, Ph.D., Chief Scientific Officer, Ablynx, *Belgium*

### Bispecific Antibodies Targeting Transferin Receptor or CD98 to Facilitate Delivery across the Blood Brain Barrier

Jasi Atwal, Scientist, Genentech

### Artificial immunotoxins

Ernst Wagner, Ph.D., Chair, Pharmaceutical Biotechnology, Center for System-based Drug Research, Center for Nanoscience, Ludwig Maximilians University, *Germany*

## ANTIBODY-DRUG CONJUGATES & FUSION PROTEINS

### Session Chair:

Gregory Adams, Ph.D., Chief Scientific Officer, Eleven Biotherapeutics

### Redox Selenium ADCs Improve Cancer Cell Monoclonal Antibody Cytotoxicity

Julian Spallholz, Ph.D., Professor, Nutritional Sciences, Texas Tech University

### Antibody-drug Conjugates for Treating Steroid-resistant Malignancies and Autoimmune Diseases

Masahiro Yasunaga, M.D., Ph.D., Unit Leader, Developmental Therapeutics, National Cancer Center, *Japan*

### Targeting Tumors and Their Vasculature with Antibody-drug Conjugates

Dimitar Dimitrov, Ph.D., Senior Investigator, CCR, Cancer and Inflammation Program, NCI-Frederick, NIH

### Novel Calicheamicin Antibody-Drug Conjugates

Julia Gavriluk, Ph.D., Principal Scientist, Discovery Chemistry, Abbvie Stemcentrx

## NOVEL ANTIBODY DISPLAY, SELECTION AND SCREENING TECHNOLOGIES

### Session Chair:

Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica

### Using Next Generation Sequencing in Antibody Libraries

Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica

### Engineering Developable Antibodies

Peter Tessier, Professor, Rensselaer Polytechnic Institute

### Advances in Yeast Display Selections for Membrane Targets

Benjamin Hackel, Ph.D., Assistant Professor, Chemical Engineering and Materials Science, University of Minnesota

### Quantitative Proteomics

Jim Wells, Professor, UCSF

### Programming Antibodies and Antigens using Deep Sequencing-Enabled Protein Engineering

Tim Whitehead, Ph.D., Associate Professor, Chemical Engineering and Materials Science, Michigan State University

### Functional Interrogation and Mining of Natively Paired Heavy:Light Human Antibody Repertoires

Department of Pharmaceutical Chemistry, The University of Kansas

---

## ROLE OF THE T-CELL REPERTOIRE IN CANCER, INFECTIOUS DISEASES AND AUTOIMMUNITY

---

### Session Chair:

Jamie K. Scott, M.D., Ph.D., Professor and Canada Research Chair in Molecular Immunity, Department of Molecular Biology & Biochemistry and Faculty of Health Sciences, Simon Fraser University, Canada

### Genetic Variation in MHC Proteins is Associated with T-cell Receptor Expression Biases

Eilon Sharon, Ph.D., Postdoctoral Fellow, Howard Hughes Medical Institute, Stanford University

### CD8 T-cell Repertoire Dynamics and Their Association with HCV Clearance

Naglaa H. Shoukry, Ph.D., Associate Professor, Department of Medicine, University of Montreal, Canada

### CD39 and CD103 Identify Tumor-reactive CD8 T-cells in Human Solid Tumors

Thomas Duhon, Ph.D., Senior Research Scientist, AgonOx

---

## ANTI-TUMOR ANTIGEN ANTIBODIES IN CANCER IMMUNOTHERAPY

---

### Session Chair:

K. Dane Wittrup, Ph.D., C.P. Dubbs Professor of Chemical Engineering and Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology

### Tumor Targeting Antibodies: Distinct Innate and Adaptive Immune Sensing

Yang-Xin Fu, M.D., Ph.D., Professor of Pathology, Mary Nell and Ralph B. Rogers Professorship in Immunology, UT Southwestern

### Innate and Adaptive Integrin-targeted Combination Immunotherapy

Jennifer R. Cochran, Ph.D., Co-Founder and Director, Nodus Therapeutics

### NK Cell Engagement with Bispecific Antibodies

Ann Cheung, Ph.D., Director of Biology, Dragonfly Therapeutics

### Anti-chaperone Antibodies in Cancer Therapy

Amy S. Lee, Ph.D., Associate Director for Basic Research, USC Norris Comprehensive Norris Cancer Center and Professor of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California

---

## NOVEL THERAPEUTIC INDICATIONS FOR ANTIBODIES

---

### Session Chair:

James Larrick, M.D., Ph.D., Managing Director and Chief Medical Officer, Panorama Research Institute and Velocity Pharmaceutical Development

### Antibody Approaches to T1D

William Ridgway, Professor, University of Cincinnati

### Action of Bispecific Anti-FGFR1/ $\beta$ Klotho Antibody in Obese Mice and Humans

Junichiro Sonoda, Ph.D., Senior Scientist, Cancer Immunology, Genentech

### Therapeutic Antibodies that Silence B Cells by Emulating Peripheral Immune Tolerance

John Cambier Ph.D., Distinguished Professor and Chair, Department of Immunology and Microbiology, University of Colorado SOM

---

## NOVEL ENGINEERING STRATEGIES TO ENHANCE ANTIBODY FUNCTIONS

---

### Session Chair:

Paul J. Carter, Ph.D., Senior Director and Staff Scientist, Antibody Engineering, Genentech, Inc.

### From Format to Function - Transformative Antibody Therapeutics

Martin Steegmaier, Ph.D., Head of Discovery, Large Molecule Research, Roche pRED, Roche Innovation Center Munich, Germany

### Anti-OX40 Agonist Antibodies

Gregory Lazar, Scientist, Genentech

### Adapted Fc-glycan changes for enhanced ADCC and/or CDC

Gestur Vidarsson, Ph.D., Head of Immunoglobulin Research/PI, Experimental Immunohematology, Sanquin Research, The Netherlands

---

## INNOVATING ANTIBODY THERAPEUTICS

---

### Session Chair:

Paul Parren, Ph.D., Senior Vice President and Scientific Director, Genmab, The Netherlands

### Evolution of Antibodies of Different Germline Gene Origins Proceed through Different Paths

Mats Ohlin, Ph.D., Professor, Department of Immunotechnology & SciLifeLab, Lund University, Sweden

### DNA-based Antibody Therapy via Antibody Gene Transfer

Kevin Hollevoet, Ph.D., Group Leader and Postdoc, Therapeutic and Diagnostic Antibodies, University of Leuven, 5

### Structural Determinants for Modulating Antibody-Fc Receptor Interactions for Half-Life Enhancement and Effector Functions

Karthik Viswanathan, Ph.D., Director, Research, Visterra, Inc.






<b>Main Conference</b> (Tues-Fri)	Register by June 30, 2017 <b>SAVE \$600</b>	Standard Rate	<b>INDUSTRY ADD-ON OPTIONS</b> Half Day Workshop (Monday PM): <b>\$499</b> Full Day Training Course (Mon): <b>\$899</b> Poster Presentation: <b>\$125</b>
<b>INDUSTRY RATES</b>	<b>\$2,099</b>	\$2,699	
<b>INDUSTRY GROUP RATES</b>	<b>\$1,899 per person</b>	\$2,499 per person	
<b>Main Conference</b> (Tues-Fri)	Register by June 30, 2017 <b>SAVE \$400</b>	Standard Rate	<b>ACADEMIC/GOVT ADD-ON OPTIONS</b> Half Day Workshop (Monday PM): <b>\$199</b> Full Day Training Course (Mon): <b>\$599</b> Poster Presentation: <b>\$0</b>
<b>ACADEMIC/GOVT* RATES</b>	<b>\$699</b>	\$1,099	
<b>ACADEMIC/GOVT* GROUP RATES</b>	<b>\$599 per person</b>	\$999 per person	

\*Academic/Government rates are extended to full-time employees of government, universities and university-affiliated hospitals only. To register for only a training course or symposia, please contact Brian Schiff at [brian.schiff@knect365.com](mailto:brian.schiff@knect365.com) or 646-895-7444.

## REGISTER A GROUP OF 4+ AND SAVE UP TO \$200/PERSON

Companies that register 4+ attendees are eligible to receive up to an additional \$200 savings per person off the current registration rate. Register your group today at the lowest rate by contacting Brian Schiff at [brian.schiff@knect365.com](mailto:brian.schiff@knect365.com) or +1-646-895-7444.



### Present a Poster to Showcase Your Company's Latest Research

Highlight your company's exciting research by presenting a scientific poster, which will be displayed in the exhibit & poster hall during the event. You must be a registered attendee to present a poster. Poster fee is \$125 for industry attendees and free for academic/government attendees. The deadline to submit your poster is November 10, 2017.



### Sponsorship/Exhibition Opportunities

Highlight your expertise directly to 800+ scientists and high level decision makers and influencers working across antibody engineering, antibody therapeutics and protein discovery and development by becoming an event sponsor or exhibitor. Contact Aimee Croke at [aimee.croke@knect365.com](mailto:aimee.croke@knect365.com) or (857) 504-6697 for pricing and package details, or to see a sample attendee list from Antibody Engineering 2016. Reserve your spot early to ensure company placement in our printed brochure.



#### Venue Information:

#### Manchester Grand Hyatt San Diego

1 Market Place, San Diego, CA 92101

Phone: (888) 421-1442

#### Special Attendee Room Rate: \$230/night + tax

Please call the hotel directly at the number above or book online and reference "Antibody Engineering" to receive the reduced room rate.

Special hotel rates are good through November 6th or until room block is sold-out.